Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.

Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement.

<h4>Background</h4>Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously report...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mélanie Bézard, Silvia Oghina, Damien Vitiello, Mounira Kharoubi, Ekaterini Kordeli, Arnault Galat, Amira Zaroui, Soulef Guendouz, Floriane Gilles, Jason Shourick, David Hamon, Vincent Audard, Emmanuel Teiger, Elsa Poullot, Valérie Molinier-Frenkel, François Lemonnier, Onnik Agbulut, Fabien Le Bras, Thibaud Damy
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/bbbf2a9e4d304b4583602af0c7c9d90b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/bbbf2a9e4d304b4583602af0c7c9d90b

Ejemplares similares